CN1838959A - Erbb2抗癌剂的给药方案 - Google Patents

Erbb2抗癌剂的给药方案 Download PDF

Info

Publication number
CN1838959A
CN1838959A CNA200480023705XA CN200480023705A CN1838959A CN 1838959 A CN1838959 A CN 1838959A CN A200480023705X A CNA200480023705X A CN A200480023705XA CN 200480023705 A CN200480023705 A CN 200480023705A CN 1838959 A CN1838959 A CN 1838959A
Authority
CN
China
Prior art keywords
methyl
inhibitor
yloxy
pyridin
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480023705XA
Other languages
English (en)
Chinese (zh)
Inventor
萨米特·K·巴塔查亚
理查德·D·康奈尔
詹姆斯·D·莫耶
吉蒂什·P·贾尼
丹尼斯·A·诺埃
斯蒂法纳斯·J·斯泰恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1838959A publication Critical patent/CN1838959A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200480023705XA 2003-08-18 2004-08-06 Erbb2抗癌剂的给药方案 Pending CN1838959A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
US60/495,919 2003-08-18

Publications (1)

Publication Number Publication Date
CN1838959A true CN1838959A (zh) 2006-09-27

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480023705XA Pending CN1838959A (zh) 2003-08-18 2004-08-06 Erbb2抗癌剂的给药方案

Country Status (18)

Country Link
US (1) US20050119288A1 (https=)
EP (1) EP1658080A1 (https=)
JP (1) JP2007502807A (https=)
KR (2) KR20060037447A (https=)
CN (1) CN1838959A (https=)
AR (1) AR045268A1 (https=)
AU (1) AU2004264726A1 (https=)
BR (1) BRPI0413745A (https=)
CA (1) CA2536140A1 (https=)
CO (1) CO5670356A2 (https=)
IL (1) IL173127A0 (https=)
MX (1) MXPA06001989A (https=)
NO (1) NO20061252L (https=)
RU (1) RU2328287C2 (https=)
SG (1) SG135193A1 (https=)
TW (1) TW200522966A (https=)
WO (1) WO2005016347A1 (https=)
ZA (1) ZA200600517B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005016346A1 (en) * 2003-08-14 2005-02-24 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005028469A1 (en) 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
CN1972688B (zh) 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-苯胺基-喹唑啉-6-基-酰胺类化合物
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
CA2610661A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
EP1890677A4 (en) * 2005-06-16 2013-01-30 Myriad Genetics Inc PHARMACEUTICAL COMPOSITIONS AND THEIR USE
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
ES2364901T3 (es) 2005-11-15 2011-09-16 Array Biopharma, Inc. Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
CA2647671A1 (en) * 2006-03-31 2007-11-01 Massachusetts Institute Of Technology Treatment of tumors expressing mutant egf receptors
AU2007234379A1 (en) * 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
WO2008124823A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Method of treating melanoma
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
CA2856803A1 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3101115B1 (en) 2014-01-31 2020-10-21 Toppan Printing Co., Ltd. Biomolecule analysis kit and biomolecule analysis method
JP7057278B2 (ja) * 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
MX9707453A (es) * 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
HRP20021005A2 (en) * 2000-06-22 2004-02-29 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
GEP20063872B (en) * 2001-12-12 2006-07-10 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production
PL373848A1 (en) * 2001-12-12 2005-09-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
WO2004046101A2 (en) * 2002-11-20 2004-06-03 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
WO2004054585A1 (en) * 2002-12-18 2004-07-01 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
RU2006102125A (ru) 2007-09-27
ZA200600517B (en) 2007-02-28
SG135193A1 (en) 2007-09-28
RU2328287C2 (ru) 2008-07-10
AR045268A1 (es) 2005-10-19
IL173127A0 (en) 2006-06-11
MXPA06001989A (es) 2006-05-17
EP1658080A1 (en) 2006-05-24
KR20080014144A (ko) 2008-02-13
KR20060037447A (ko) 2006-05-03
AU2004264726A1 (en) 2005-02-24
BRPI0413745A (pt) 2006-10-24
CO5670356A2 (es) 2006-08-31
CA2536140A1 (en) 2005-02-24
JP2007502807A (ja) 2007-02-15
US20050119288A1 (en) 2005-06-02
TW200522966A (en) 2005-07-16
NO20061252L (no) 2006-05-16
WO2005016347A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
CN1838959A (zh) Erbb2抗癌剂的给药方案
CN1177833C (zh) 取代的间二氮杂萘衍生物
TWI758623B (zh) Ｂｃｌ-２抑制劑與ＢＴＫ抑制劑的組合產品在預防和/或治療疾病中的用途
CN100351241C (zh) 喹唑啉胺盐酸盐的稳定多晶形物及其制备方法和医药用途
CN1100540C (zh) 具有选择性抑制her－2自磷酸化性质的蛋白质酪氨酸激酶芳基和杂芳基喹唑啉化合物
US8426428B2 (en) EGFR kinase knockdown via electrophilically enhanced inhibitors
JP5740409B2 (ja) キナーゼ阻害剤
CN101035536A (zh) 有机化合物的组合
CN1909908A (zh) 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物
CN117357650A (zh) 包含sos1抑制剂的药物组合物
CN1856327A (zh) Vegf受体抑制剂与化疗剂的组合
TW201728583A (zh) 氨基噻唑化合物及其用途
CN1791396A (zh) 组蛋白脱乙酰基酶抑制剂与化疗剂的组合
JP2011513364A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用
MXPA06005024A (es) Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer.
TWI667236B (zh) 作為蛋白激酶抑制劑的胺基噻唑化合物
EP3174869B1 (en) Combination therapy of a met inhibitor and an egfr inhibitor
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
TWI774780B (zh) 化合物
BRPI0717873A2 (pt) Derivado de 3-amino-pirazol-4-carboxamida úteis como inibidores de proteína quinases
HK1091745A (en) Dosing schedule for erbb2 anticancer agents
WO2016025641A1 (en) Combinations of an erk inhibitor and an egfr inhibitor and related methods
EP4034121A1 (en) Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors
CN103313713B (zh) 受体型激酶调节剂和多囊性肾病的治疗方法
CN1711088A (zh) 治疗癌症的方法及相关方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1091745

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060927

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1091745

Country of ref document: HK